AI Generated Image
Ozempic and Wegovy may strengthen bones in Type 2 diabetes patients, study finds
New York Post • • health
Key Points:
- A new study suggests that semaglutide, the active ingredient in weight-loss drugs Ozempic and Wegovy, may strengthen bones in type 2 diabetes patients while aiding weight loss.
- Researchers found that patients taking semaglutide were 15% less likely to experience bone fractures compared to those using other weight-loss medications.
- The study analyzed medical records of over 59,000 adults with type 2 diabetes, noting 794 fractures among 26,324 semaglutide users versus 1,045 fractures in 33,555 patients on other drugs.
- These findings challenge concerns that rapid weight loss might weaken bones and highlight the importance of monitoring bone health in weight-loss programs.
- The research was presented at the Endocrine Society’s ENDO 2026 meeting, emphasizing its significance for older adults at risk of bone loss.
